Abstract |
The most disabling symptom for most patients with unilateral Meniere's disease is vertigo. Eradication of the diseased end organ is effective in eliminating the vertigo. Labyrinthectomy remains the "gold standard"; unfortunately, residual hearing is sacrificed to obtain this end. The purpose of this study is to evaluate low-dose intratympanic gentamicin for the control of vertigo and for the preservation of hearing. A single dose of gentamicin (10-80 mg) was injected into the middle ear space of 23 patients with unilateral Meniere's disease as an office procedure. Eighty-four percent of the patients had no episodes of vertigo during the last 6 months of follow-up. Pure tone average and word discrimination scores were unchanged as a group. Ninety-five percent of patients had a hearing loss at 6 and 8 kHz that averaged 7.5 dB. Caloric function was reduced in 93%. Low-dose intratympanic gentamicin is a safe, simple, office procedure that is effective in controlling the definitive vertiginous episodes in most patients with unilateral Meniere's disease. Control of vertigo can be obtained with preservation of hearing.
|
Authors | C L Driscoll, J L Kasperbauer, G W Facer, S G Harner, C W Beatty |
Journal | The Laryngoscope
(Laryngoscope)
Vol. 107
Issue 1
Pg. 83-9
(Jan 1997)
ISSN: 0023-852X [Print] United States |
PMID | 9001270
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Gentamicins
|
Topics |
- Absorption
- Administration, Topical
- Adult
- Aged
- Anti-Bacterial Agents
(administration & dosage)
- Audiometry, Pure-Tone
- Electronystagmography
- Female
- Gentamicins
(administration & dosage)
- Humans
- Male
- Meniere Disease
(drug therapy)
- Middle Aged
- Prospective Studies
- Treatment Outcome
- Tympanic Membrane
- Vertigo
(drug therapy)
|